For the Inventor, By the Inventor

Enter inventor name

Ann Arbor, MI, United States of America

Chao-Yie Yang

USPTO Granted Patents = 15 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 8.1

ph-index = 5

Forward Citations = 72(Granted Patents)

Company Filing History:

14 out of 3,370

University of Michigan

Ascentage Pharma (suzhou) Co., Ltd.

Ascentage Pharma Group Corp Limited

Jiangsu Ascentage Biomed Development Inc.

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319703 - Macrocyclic fused pyrazoles as Mcl-1 inhibitors (2025-06-03),

2. 12145944 - Imidazopyrimidines as EED inhibitors and the use thereof (2024-11-19),

3. 11691989 - Macrocyclic indoles as Mcl-1 inhibitors (2023-07-04),

4. 11548899 - Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors (2023-01-10),

5. 11498928 - Macrocyclic spiroethers as Mcl-1 inhibitors (2022-11-15),

6. 11168082 - Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors (2021-11-09),

7. 10781208 - 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors (2020-09-22),

8. 10759808 - Monofunctional intermediates for ligand-dependent target protein degradation (2020-09-01),

9. 10633386 - BET protein degraders (2020-04-28),

10. 10391175 - BET bromodomain inhibitors and therapeutic methods using the same (2019-08-27),

11. 9783539 - Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors (2017-10-10),

12. 9675697 - BET bromodomain inhibitors and therapeutic methods using the same (2017-06-13),

13. 8691184 - Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same (2014-04-08),

14. 7932382 - Conformationally constrained Smac mimetics and the uses thereof (2011-04-26),

15. 7674787 - Conformationally constrained Smac mimetics and the uses thereof (2010-03-09),

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…